Literature DB >> 1398472

Histology of skeletal muscle in adults with GH deficiency: comparison with normal muscle and response to GH treatment.

R C Cuneo1, F Salomon, C M Wiles, J M Round, D Jones, R Hesp, P H Sönksen.   

Abstract

The histology of needle biopsy specimens of skeletal muscle from the vastus lateralis was quantitatively assessed in a group of adults with growth hormone (GH) deficiency, most of whom had hypopituitarism treated with conventional pituitary hormone replacement. The mean age of the 21 patients (16 males and 5 females) was 39 +/- 2 (SEM). Comparisons were made with age- and sex-matched controls following six months double-blind, placebo-controlled treatment with recombinant human GH (rhGH) in the GH-deficient patients. Before treatment, needle muscle biopsies from patients with GH deficiency showed mean type I and II fibre areas of 5,153 +/- 273 and 4,828 +/- 312 microns 2 respectively, which did not differ from the controls (4,482 +/- 306 and 4,699 +/- 310 microns 2). Percentages of type I fibres were similar in the two groups (47.2 +/- 2.5% in GH deficiency and 45.3 +/- 2.2% in controls). No difference in the variability of type I or II fibre areas was demonstrated between the groups. Correlations between the relative contribution to total fibre area by type I fibres (mean fibre area x percent) and maximal oxygen uptake (p = 0.006), and between type II fibres and quadriceps force (p = 0.035) were noted in GH-deficient adults before treatment. Following rhGH treatment, no change was noted in mean fibre areas, variability of fibre areas, or percentage of either fibre type.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1398472     DOI: 10.1159/000182276

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  9 in total

1.  Problems with GH doping in sports.

Authors:  M Bidlingmaier; Z Wu; C J Strasburger
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

Review 2.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

Review 3.  Claims for the anabolic effects of growth hormone: a case of the emperor's new clothes?

Authors:  M J Rennie
Journal:  Br J Sports Med       Date:  2003-04       Impact factor: 13.800

Review 4.  Use of growth hormone, IGF-I, and insulin for anabolic purpose: Pharmacological basis, methods of detection, and adverse effects.

Authors:  Lindsey J Anderson; Jamie M Tamayose; Jose M Garcia
Journal:  Mol Cell Endocrinol       Date:  2017-06-09       Impact factor: 4.102

5.  Growth hormone substitution titrated to obtain IGF-I levels in the physiological range in hypopituitary adults: effects upon dynamic strength, endurance and EMG.

Authors:  Bertil Ekman; Björn Gerdle; Hans J Arnqvist
Journal:  Eur J Appl Physiol       Date:  2003-07-26       Impact factor: 3.078

6.  Elevation of serum creatine phosphokinase during growth hormone treatment in patients with multiple pituitary hormone deficiency.

Authors:  T Momoi; C Yamanaka; R Tanaka; A Yoshida; M Okumura; S Yamakura; Y Takasaki; H Sasaki; M Kawai
Journal:  Eur J Pediatr       Date:  1995-11       Impact factor: 3.183

Review 7.  Regulation of muscle mass by growth hormone and IGF-I.

Authors:  C P Velloso
Journal:  Br J Pharmacol       Date:  2008-06       Impact factor: 8.739

8.  Association of insulin resistance and nocturnal fall of blood pressure in GH-deficient adults during GH replacement.

Authors:  R Resende de Lima Oliveira Brasil; D Vieira Soares; L Diniz Carneiro Spina; P Marise Lobo; E Maria Carvalho da Silva; V Aleta Mansur; M F Miguens Castelar Pinheiro; F L Conceição; M Vaisman
Journal:  J Endocrinol Invest       Date:  2007-04       Impact factor: 4.256

Review 9.  Effects of growth hormone on body composition and bone metabolism.

Authors:  A L Carrel; D B Allen
Journal:  Endocrine       Date:  2000-04       Impact factor: 3.925

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.